Skip to main content
The Dutch southwest Early psoriatic arthritis (PsA) cohort study has demonstrated that the earlier the referral and diagnosis of PsA, the better the outcome. 
Disparities in SLE care: adult Medicare cohort study of 1,036 SLE pts found 39% saw a rheumatologist q 6 mos & 28% h

Dr. John Cush RheumNow

2 years 3 months ago
Disparities in SLE care: adult Medicare cohort study of 1,036 SLE pts found 39% saw a rheumatologist q 6 mos & 28% had serologic tests. Least disadvantaged quintile had higher visit-based retention, but decreased serologic testing (aOR 0.80) https://t.co/lGoriPIMqV https://t.co/JF0RWZxRoU
Best Selling US Drugs in 2023
11 Skyrizi $10.1 billion
10 Dupixent $11.5 b
9 Biktarvy $13.15 b
8 Mounjaro $13.16 b
7

Dr. John Cush RheumNow

2 years 3 months ago
Best Selling US Drugs in 2023 11 Skyrizi $10.1 billion 10 Dupixent $11.5 b 9 Biktarvy $13.15 b 8 Mounjaro $13.16 b 7 Keytruda $15.4 b 6 Stelara $15.87 b 5 Jardiance $15.89 b 4 Trulicity $16.3 b 3 Eliquis $22.1 b 2 Humira $35.3 b 1 Ozempic $38.6 b https://t.co/tiEwqyTB6D https://t.co/xghijiRFtW
Remaining status quo requires less effort than making a change. Over the last 20+ years, I have listened to thousands of patients confide their personal stories. Some remained paralyzed in their current state of distress, fearing new situations may be worse. I was one of them, until recently. In this final blog of my trilogy on self-discovery, I reveal my new life.
384 Psoriasis pts followed mean 33 mos, 56 (14.6%) developed new-onset PsA. 311/384 (81%) had arthralgia (subclinical Ps

Dr. John Cush RheumNow

2 years 3 months ago
384 Psoriasis pts followed mean 33 mos, 56 (14.6%) developed new-onset PsA. 311/384 (81%) had arthralgia (subclinical PsA) & 9.4% got PsA within 12 mos (23% by 36%). Subclinical more likely than PSO to get PsA (OR 11.7) https://t.co/D7n3ZpJURH https://t.co/vJcFgRcbx4
NON-treatment of 18,318 VA pts (RA, SpA, PsA) = 41% not Rx DMARDs w/in 12 mos of Dx. Signif higher odds if Black (HR 1.1

Dr. John Cush RheumNow

2 years 3 months ago
NON-treatment of 18,318 VA pts (RA, SpA, PsA) = 41% not Rx DMARDs w/in 12 mos of Dx. Signif higher odds if Black (HR 1.13), Hispanic (1.14), Charlson Comorbidity ≥2 (1.15), opiate use (1.09). DMARD use ^ if married, w/ erosions, female MD, Rheum Dx https://t.co/TaYC27oIOz https://t.co/qjfAGI5L5g
Mayo Derm Study of 335 #SLE pts: 231 w/ skin manifestations. LE specific skin Dz signif assoc w/ photosensitivity, SM &a

Dr. John Cush RheumNow

2 years 3 months ago
Mayo Derm Study of 335 #SLE pts: 231 w/ skin manifestations. LE specific skin Dz signif assoc w/ photosensitivity, SM & U1RNP Abs. Pts w/ 2–4 mucocutaneous ACR criteria had less cytopenia & dsDNA Abs (P=0.004), but no assoc w/ systemic Dz https://t.co/f7PEerxKZw https://t.co/9kRW724cPq
Full read review of the benefits & impact of hydroxychloroquine in #SLE. Benefits on:
- T cells, cytokines, TLR sign

Dr. John Cush RheumNow

2 years 3 months ago
Full read review of the benefits & impact of hydroxychloroquine in #SLE. Benefits on: - T cells, cytokines, TLR signaling - VTE prevention - Decr CV risks - Glucose & lipid benefits - Pregnancy https://t.co/z9cooQwZux https://t.co/QumKoHgQDY
FAERS retrospective, safety study of JAKi use in 75K RA pts (52K Tofa; 21K Upa, 2.2K Bari vs bDMARDs) found JAKi had inc

Dr. John Cush RheumNow

2 years 3 months ago
FAERS retrospective, safety study of JAKi use in 75K RA pts (52K Tofa; 21K Upa, 2.2K Bari vs bDMARDs) found JAKi had incr risk of VTE (adj ROR=2.11), CVA (ROR=1.25), IHD (1.23), edema(1.22), & tachyarrhythmias (1.15) https://t.co/Bvds4C66Nq https://t.co/Xmu8g35MXR
Brazilian Registry of Spondyloarthritis study of 1096 SpA pts, found 73% HLA-B27 positivity. B27+ signif assoc w/ males,

Dr. John Cush RheumNow

2 years 3 months ago
Brazilian Registry of Spondyloarthritis study of 1096 SpA pts, found 73% HLA-B27 positivity. B27+ signif assoc w/ males, earlier onset/Dx, uveitis, +FHx. B27 negativity assoc w/ psoriasis, higher peripheral arthritis/disease activity, worse QOL, mobility https://t.co/ousSetEnrt https://t.co/ezSgHro8sQ
MarketScan Claims & Medicaid study of incident AS, PsA, or RA (2010–2017) that Opioid use was highly prevalent in

Dr. John Cush RheumNow

2 years 3 months ago
MarketScan Claims & Medicaid study of incident AS, PsA, or RA (2010–2017) that Opioid use was highly prevalent in AS (36%), PsA (30%), & RA (44%) in the year prior to Dx & during the 1st Yr. Is this PCP or Rheumatologist mismanagement? https://t.co/YsCOLZUCfS https://t.co/b33uNg6Ucx
Insurance claims data studied 7580 newly Dx RA (2018-2020) - 1998 tofacitinib vs 5582 adalimumab. After propensity matc

Dr. John Cush RheumNow

2 years 3 months ago
Insurance claims data studied 7580 newly Dx RA (2018-2020) - 1998 tofacitinib vs 5582 adalimumab. After propensity matching, dyslipidemia was signif. higher w/ TOFA (HR 1.25), BUT no differences in MACE (HR 0.995) or all-cause mortality (HR, 1.4; NS) https://t.co/ZJ7uHWTycS https://t.co/A6tSm4RipS
Annals of Internal Medicine reports a study of more than 75,000 persons screened for monoclonal gammopathy of undetermined significance (MGUS) and found no association between autoimmune rheumatic disease (AIRD) and MGUS.While MGUS may be a precursor to multiple myeloma, the observations of MGUS with AIRD questions the association. 
A longitudinal, multinational study shows that SLE patients achieving remission or low disease activity incur lower overall direct/indirect (DCs, ICs) healthcare costs than those with persistent activity. 
Legal (Not So) Merry-Go-Round of Alendronate Atypical Fractures

Dr. Gregory Curfman, MD writes on the chronological le

Dr. John Cush RheumNow

2 years 3 months ago
Legal (Not So) Merry-Go-Round of Alendronate Atypical Fractures Dr. Gregory Curfman, MD writes on the chronological legal progress of a lawsuit stemming from rare instances of atypical femoral fractures associated with bisphosphonate (alendronate) use. https://t.co/6Ipvw7tcKr https://t.co/VNrMg88AsH
×